J.P. Morgan Private Wealth Advisors LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.

Quarter-by-quarter ownership
J.P. Morgan Private Wealth Advisors LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$754,472
-19.3%
14,484
-1.9%
0.00%
-60.0%
Q2 2023$935,110
+9.1%
14,768
-6.7%
0.01%
+150.0%
Q1 2023$856,924
+22.7%
15,825
+19.9%
0.00%0.0%
Q4 2022$698,226
+51.8%
13,194
+33.4%
0.00%
+100.0%
Q3 2022$460,000
+83.3%
9,888
+124.6%
0.00%0.0%
Q2 2022$251,000
-3.5%
4,403
+3.6%
0.00%0.0%
Q1 2022$260,0004,2490.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 675,000$26,203,0007.44%
EcoR1 Capital, LLC 244,950$9,509,0003.75%
Redmile Group, LLC 971,565$37,716,0003.60%
Ghost Tree Capital, LLC 120,000$4,658,0001.34%
SENZAR ASSET MANAGEMENT, LLC 144,624$5,614,304,0001.22%
GREAT POINT PARTNERS LLC 100,000$3,882,0001.11%
BB BIOTECH AG 700,000$27,174,0001.07%
Rhenman & Partners Asset Management AB 115,000$4,464,0000.79%
Lisanti Capital Growth, LLC 12,260$476,0000.72%
Rock Springs Capital Management LP 190,000$7,376,0000.55%
View complete list of INTRA CELLULAR THERAPIES INC shareholders